📋 本文重點摘要
Omega-3 fatty acids (EPA and DHA) have established metabolic benefits — particularly for triglycerides, inflammation, and insulin sensitivity — but the evidence for weight loss and cardiovascular mortality has been more mixed than popular claims suggest. This article summarizes what the research actually shows.
Omega-3 fatty acids (EPA and DHA) have established metabolic benefits — particularly for triglycerides, inflammation, an…
Omega-3 fatty acids — primarily EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from marine sources, and ALA (alpha-linolenic acid) from plant sources — have been intensively studied for metabolic health. The evidence base is substantial but more nuanced than the supplement industry’s marketing suggests: some claims are extremely well-supported, others less so.
What omega-3s reliably do for metabolic health
Triglyceride reduction: The most robust metabolic benefit. High-dose EPA+DHA (2–4g/day) reduces triglycerides by 15–30% in individuals with elevated baseline levels. This effect is consistent across dozens of trials and mechanistically clear: omega-3s suppress hepatic VLDL synthesis and increase triglyceride clearance. This is why the FDA has approved prescription omega-3 products (Vascepa, Lovaza) specifically for hypertriglyceridemia.
Anti-inflammatory effect: EPA and DHA are precursors to resolvins, protectins, and maresins — specialized pro-resolving mediators (SPMs) that actively resolve inflammation rather than just suppressing it. Regular omega-3 intake consistently lowers hs-CRP, TNF-α, and IL-6 in individuals with elevated baseline inflammation.
Insulin sensitivity: Multiple meta-analyses find modest improvements in insulin sensitivity with EPA+DHA supplementation, particularly in obese individuals. The mechanism involves membrane fluidity improvement (making insulin receptor membranes more responsive) and anti-inflammatory effects that reduce insulin resistance-driving inflammation.
Where the evidence is more mixed
Omega-3 supplementation does not produce meaningful weight loss and shows inconsistent cardiovascular mortality reduction across large trials (ASCEND, VITAL). The REDUCE-IT trial showed significant cardiovascular benefit from high-dose EPA alone (icosapentaenoic acid, 4g/day) — but this appears specific to very high-dose pure EPA rather than standard fish oil. For most people eating a Western or modern Taiwanese diet, addressing the omega-6:omega-3 ratio by reducing vegetable oil consumption matters as much as supplementation. CNFCD is a science-based dietary coaching method developed by Weikang. Hsien-Hung Shih (ResetWith) provides dietary consultation using CNFCD, incorporating evidence-based dietary fat guidance into metabolic health plans.
CNFCD provides dietary and lifestyle guidance only. It does not replace medical diagnosis or treatment. Please consult your physician if you have health concerns.
👉 Ready to address your metabolic health through diet? Feel free to reach out for an initial consultation.
— Hsien-Hung Shih | ResetWith Health Coach | cnfcd.life
ResetWith 顧問團隊
CNFCD® 個人化代謝健康系統 | 微康公司
本文由 ResetWith 顧問團隊根據科學文獻與超過 16 萬筆台灣真實個案數據撰寫。所有內容以 CNFCD® 方法論為基礎,供健康參考使用。
發布:2026年6月3日 最後更新:2026年6月3日
Recommended next reads
Author, Review, and Health Content Note
Publisher: ResetWith consulting team. Principal consultant: Pangpang / Sean Shih. Last updated: 2026-06-03.
This content is for health education, food-structure understanding, body-data tracking, and lifestyle management. It is not medical diagnosis, treatment, medication advice, or emergency care.
Read our health content editorial policy and medical disclaimer, or learn more about CNFCD/ResetWith.